EP Patent

EP4137132A1 — Solid dispersion forms of rifaximin

Assigned to Salix Pharmaceuticals Inc · Expires 2023-02-22 · 3y expired

What this patent protects

Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.

USPTO Abstract

Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.

Drugs covered by this patent

minocycline-hydrochloride (MINOCYCLINE HYDROCHLORIDE)

Patent Metadata

Patent number: EP4137132A1
Jurisdiction: EP
Classification: —
Expires: 2023-02-22
Drug substance claim: No
Drug product claim: No
Assignee: Salix Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.